Natco Pharma Sets Terms for Rs 1,300 Crore Rights Issue

Natco Pharma will meet on September 25, 2026, to finalize a Rs 1,300 crore capital raise via a rights issue.
The board will determine the issue price, entitlement ratio, and record date for existing shareholders.

Reader Takeaway: The upcoming meeting will clarify equity dilution and subscription costs for existing investors in the company.

What just happened

Natco Pharma Limited has officially scheduled a board meeting for September 25, 2026. This follows the initial board approval for a fundraising exercise announced earlier this month. The company plans to raise up to Rs 1,300 crore through a rights issue of equity shares, with a face value of Rs 2 per share.

Why this matters

For existing shareholders, the rights issue represents a chance to acquire additional shares, likely at a discount to the prevailing market price. However, it also introduces the prospect of equity dilution. The specific terms—particularly the entitlement ratio and the subscription price—will dictate the financial impact on current holdings.

Governance and Compliance

In accordance with SEBI (Prohibition of Insider Trading) Regulations, the company has closed its trading window for designated persons and employees. This closure began on September 23, 2026, and will remain in effect until 48 hours after the board’s decisions are publicly disclosed.

What to track next

Investors should monitor the BSE and NSE filing archives on September 25 for the official outcome of the board meeting. Key metrics to watch include the record date, which will establish who is eligible to participate, and the final price of the rights shares compared to the current market price.